Drugs / STSP-0902
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06948799 | May 2025 → Jul 2026 overdue | oligospermia | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Recruiting | No outcome recorded |
| Phase 1 | NCT06597422 | Oct 2024 → Jan 2025 | neurotrophic keratopathy | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT06563713 | Jul 2024 → Feb 2025 | oligospermia | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06975748 | Jun 2025 → Apr 2026 overdue | neurotrophic keratopathy | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STSP-0902 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06563713 ↗ |
| Route | Subcutaneous | “STSP-0902 subcutaneous injection” NCT06563713 ↗ |